Buprenorphine/samidorphan - Alkermes

Drug Profile

Buprenorphine/samidorphan - Alkermes

Alternative Names: ALKS 33-BUP; ALKS 33/buprenorphine; ALKS-5461; BUP-ALKS 33; Buprenorphine/ALKS-33; Buprenorphine/RDC 0313; RDC 0313/buprenorphine; Samidorphan/buprenorphine

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alkermes
  • Developer Alkermes plc
  • Class Amides; Antidepressants; Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Major depressive disorder
  • No development reported Cocaine abuse

Most Recent Events

  • 01 Nov 2018 Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee reviews NDA and communicates that the benefit-risk profile of buprenorphine/samidorphan is not adequate to support approval in Major depressive disorder
  • 30 Oct 2018 The New Drug Application review for the adjunctive treatment of Major depressive disorder by Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee is planned in November 2018
  • 30 Oct 2018 Pooled safety data for FORWARD-4 and FORWARD-5 trials in Major depressive disorder released by Alkermes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top